These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 17660958)

  • 1. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
    Lin A; Rugo HS
    Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-positive breast cancer: current and future treatment strategies.
    Engel RH; Kaklamani VG
    Drugs; 2007; 67(9):1329-41. PubMed ID: 17547474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
    Haq B; Geyer CE
    Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
    Nanda R
    Rev Recent Clin Trials; 2007 May; 2(2):111-6. PubMed ID: 18473995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.